Genomic Testing   

Will you test HER2 IHC upfront for all? Or wait until later in the disease course, once a patient has exhausted other standard of care options?

Assuming no other actionable mutations.

Or can we rely on NGS testing to determine eligible patients?

Per NCCN exclusion of EGFR/ALK alterations at a minimum is recommended prior to consideration of neoadjuvant chemoimmunotherapy.

Should testing for germline mutations -- eg. saliva sample -- occur before or after the completion of chemotherapy - or the timing does not matter?&nb...

If so, what alterations would be helpful to narrow the diagnosis?